The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
A double-blinded, randomized, parallel-controlled study on the safety and efficacy of ebastine for the treatment of chronic idiopathic urticaria
Author(s): 
Pages: 307-309
Year: Issue:  5
Journal: JOURNAL OF CLINICAL DERMATOLOGY

Keyword:  荨麻疹特发性慢性依巴斯汀西替利嗪;
Abstract: 目的:评估国产依巴斯汀治疗慢性特发性荨麻疹的临床疗效和安全性.方法:采用随机、双盲、平行对照的方法对依巴斯汀治疗慢性荨麻疹进行Ⅱ期临床试验,并与西替利嗪进行对照.结果:共观察患者136例,依巴斯汀组69例,西替利嗪组67例,依巴斯汀组的有效率和显效率分别为91.3%和63.8%,而西替利嗪组分别为87.9%和65.2%,两组间比较差异均无显著性(P>0.05).依巴斯汀组症状积分下降指数为0.79±0.26,而西替利嗪组为0.76±0.29,两组间比较差异无显著性(P>0.05).两种药物的不良反应主要为轻至中度困倦和口干.结论:依巴斯汀治疗慢性特发性荨麻疹安全有效,其疗效及不良反应与西替利嗪相似.
Related Articles
No related articles found